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Abstract Multiple genetic polymorphisms of the human dopa-
mine D4 receptor (hD4R) have been identified including a 12 bp
repeat in exon 1 associated with a psychotic condition called
delusional disorder. Competition binding assays revealed minor
pharmacological differences between the recombinant A1 (nor-
mal) and A2 (delusional) proteins with respect to quinpirole and
the antipsychotic clozapine, however no functional differences
were detected for receptor activation by dopamine, epinephrine,
or norepinephrine. Our results suggest that this polymorphism
may only confer susceptibility to delusional disorder in
combination with other genetic or environmental factors.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Disturbances in dopaminergic pathways have been impli-
cated in the etiology of several psychiatric disorders, and
brain dopamine receptors are a key target for drugs used in
the treatment of psychosis. Dopamine acts through ¢ve dis-
tinct dopamine receptor subtypes, D1^D5, which have been
cloned and characterized. Among them, the dopamine D4
receptor (D4R) gene has received considerable attention in
light of its anatomical, pharmacological, and structural fea-
tures (reviewed in [1]). Moreover, among the dopamine recep-
tor genes, D4R shows a uniquely high degree of genetic var-
iation in the human population, with a 2^10-fold repeated
region of 48 bp in the third exon of its coding sequence. Other
known D4R gene polymorphisms include a polymorphic 12
bp repeat in exon 1 [2], a TPG coding transition at nucleotide
581 [3], and the presence of a nonsense 13 bp deletion in exon
1 [4]. More recently, two novel polymorphisms and a rare
deletion variant have been reported [5].
The 12 bp repeat in exon 1 encodes a sequence of four
amino acids in the extracellular N-terminal part of the recep-
tor, which borders the ¢rst putative transmembrane domain.
This sequence occurs as a two-fold repeat in the more com-
mon variant (A1 allele) and is represented only once in the
rarer one (A2 allele). Previous results have suggested the in-
volvement of this genetic variation in conferring susceptibility
to delusional disorder [2]. Delusional disorder shows some of
the same symptoms as schizophrenia, but di¡ers in its course
and pharmacological response [6,7]. Interestingly, patients suf-
fering from delusional disorder respond poorly to neuroleptics
[8,9], suggesting that this deletion may a¡ect the pharmaco-
logical properties of D4R. These data prompted us to inves-
tigate possible functional consequences of this particular var-
iant of the receptor.
2. Materials and methods
2.1. Materials
(3)Epinephrine, dopamine, haloperidol, (+)butaclamol, clozapine,
lisuride, quinpirole, 7-OH-DPAT, sulpiride, loxapine, risperidone, thi-
oridazine, chlorpromazine, doxepine, mianserine, 8-OH-DPAT, DOI
and D-cycloserine were purchased from Research Biochemicals Inter-
national (RBI). Norepinephrine and NMDA were obtained from Sig-
ma, and 5-HT from Fluka. Raclopride was the kind gift of Nina
Mohell, Astra (Sweden). Bromocryptine, pimozide, clomipramine,
clonidine, £uvoxamine, £uoxetine, DZP, DMCM, L-DOPA,
L745870, and Ro 15-4513 were obtained from the Roche chemical
library. [3H]Spiperone (89 Ci/mmol) and [35S]GTPQS (1000 Ci/mmol)
were purchased from Amersham. G418 and penicillin/streptomycin
(10 000 units/10 000 Wg, PS) were purchased from Gibco BRL, and
fetal calf serum (FCS) was obtained from Amimed.
2.2. D4R variant expression constructs
The cDNA for the previously reported human D4.4R A1 allele [10]
was subcloned into the HindIII/XbaI sites of pcDNA3 to create the
expression plasmid pcDNA3-hD4.4-A1. A PCR fragment containing
the entire exon 1 was generated from genomic DNA obtained from an
individual homozygous for the 12 bp deletion using two primers bear-
ing BamH1 plus EcoRI and HindIII plus EcoRI restriction sites, re-
spectively. This fragment was digested with HindIII/EarI and ligated
to the 1050 bp EarI/XbaI fragment of pcDNA3-hD4.4-A1 to recon-
struct the D4R A2 allele, which was subcloned into the HindIII/XbaI
sites of pcDNA3 to create the pcDNA3-hD4.4-A2 expression plasmid.
Expression plasmids were sequenced on both strands using the ABI
Prism Taq DyeDeoxy Terminator Cycle Sequencing Kit and a Model
310A Genetic Analyzer from Applied Biosystems, and analyzed using
the Sequence Analysis Software and Sequence Navigator (Applied
Biosystems).
2.3. Production of stable cell lines
CHO-K1 cells were grown to 80% con£uence in a six well Nunc
plate, washed, and incubated for 30 min at 37‡C in Optimem-Gluta-
max medium (Gibco). 2 Wg of plasmid DNA (pcDNA3-hD4.4-A1 or
pcDNA3-hD4.4-A2) and 12 Wl lipofectamine (Gibco) were added to a
total of 200 Wl Optimem medium and incubated at room temperature
for 30 min, then added dropwise to the cells. Six hours later cells were
trypsinized, suspended in 100 ml selection medium (DMEM-F12, 1%
PS, 5% FCS, 1 mg/ml G418), and plated into 100 mm dishes. Twelve
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days later cell colonies were transferred to 24 well plates. Cell clones
were analyzed for surface expression of D4R protein using £ow cy-
tometry with the DFR1 monoclonal antibody as described in [11].
Positive clones were expanded and D4R expression was con¢rmed
by saturation binding with [3H]spiperone. Two cell clones, CHO-
hD4.4-A1 and CHO-hD4.4-A2, were chosen for detailed pharmaco-
logical pro¢ling.
2.4. Immunoblotting
CHO cells were transfected with pcDNA3-hD4.4-A1 or pcDNA3-
hD4.4-A2 plasmids using lipofectamine as described above, and crude
membrane fractions were prepared as described in [11]. Proteins were
separated by 10% SDS-PAGE with a 4% stacking gel, transferred to
nitrocellulose membrane, and immunoblotted with DFR1 antibody (1
Wg/ml) at 4‡C for 18 h. Labeled proteins were detected using horse-
radish peroxidase goat anti-mouse IgG (H+L) (Chemicon, 1:3000
dilution) with enhanced chemiluminescence according to manufactur-
er’s instructions (ECL, Amersham). Protein content was determined
by the BCA assay method.
2.5. Binding assays
CHO-hD4.4-A1 and CHO-hD4.4-A2 stable cell lines were grown to
80% con£uence and harvested using 0.02% EDTA in PBS. Cell mem-
branes were prepared and binding assays performed as described in
[12].
2.6. [35S]GTPQS binding assay
[35S]GTPQS binding assays were performed as described in [12].
Bmax values were determined directly for the GTPQS membrane prep-
arations, and are noted in Section 3.
3. Results
3.1. Expression of D4R A1 and A2 allele variants
The cDNA encoding the full-length D4.4R [10], referred to
as the A1 allele, was subcloned into the pcDNA3 expression
vector (pcDNA3-hD4.4-A1). The D4R isoform carrying four
copies of the putative third cytoplasmic loop repeat (called
D4.4) was chosen, since this is the most abundant in the
human population [13]. In order to construct the A2 variant,
an entire exon 1 fragment was generated by PCR from ge-
nomic DNA obtained from an individual homozygous for the
12 bp deletion. This fragment was used to replace the corre-
sponding sequence in pcDNA3-hD4.4-A1 resulting in a sec-
ond expression construct, pcDNA3-hD4.4-A2.
CHO cells were transiently transfected with pcDNA3-
hD4.4-A1 and pcDNA3-hD4.4-A2 plasmids, and crude mem-
branes were analyzed for D4R expression by immunoblot
analysis with the monoclonal antibody DFR1 [11]. A 47
kDa band was observed in both transfections con¢rming
that the expression constructs encoded full-length D4R pro-
teins (Fig. 1). The size of this band suggested that it did not
contain glycosylation since it corresponded to the calculated
molecular weight of the D4.4R polypeptide. No DFR1 immu-
noreactivity was observed in untransfected CHO cells, as ex-
pected. D4R aggregates observed at 90 and 130 kDa probably
occur as a result of the high level of D4R protein expression
since they were not observed in the stable CHO-D4.4 cell line
reported previously [11].
CHO cells stably expressing the A1 and A2 D4R isoforms
were obtained by transfection with pcDNA3-hD4.4-A1 and
pcDNA3-hD4.4-A2 plasmids followed by selection in the
presence of G418. A total of 24 clones of each variant were
analyzed by £ow cytometry with the monoclonal antibody
DFR1 [11], from which four clones with the highest surface
labeling were selected for expansion. Saturation binding anal-
ysis with [3H]spiperone revealed two cell lines of interest,
CHO-hD4.4-A1 and CHO-hD4.4-A2, which had Bmax values
of 0.56 þ 0.03 and 1.97 þ 0.17 pmol/mg protein, respectively.
Scatchard analysis of [3H]spiperone binding revealed binding
constants (KD values) of 371 þ 30 pM and 357 þ 40 pM (n = 3)
for A1 and A2 variants, respectively (Fig. 2). This is in good
agreement with published values for [3H]spiperone binding to
the D4.4R in CHO cells [12], and demonstrated no di¡erence
in a⁄nity for spiperone between the A1 and A2 D4R variants.
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Fig. 1. Western blot analysis of A1 and A2 dopamine D4R variants
with the monoclonal antibody DFR1. CHO cells were transiently
transfected with pcDNA3-hD4.4-A1 and pcDNA3-hD4.4-A2 plas-
mids and crude membranes were separated by SDS-PAGE. A 47
kDa band corresponding to the D4R protein was labeled by DFR1
in both A1 and A2 membrane preparations, and no labeling was
detected in untransfected CHO cells. Higher molecular weight D4R
aggregates are also observed of approximately 95 and 150 kDa.
1 Wg protein was loaded per lane, and ¢lm exposure time was 20 s.
Table 1
Inhibition constants (Ki values) of catecholamines at hD4.4R A1 and A2 variants
hD4.4-A1 hD4.4-A2
High a⁄nity Low a⁄nity High a⁄nity Low a⁄nity
Ki (nM) % of totala Ki (nM) Ki (nM) % of totala Ki (nM)
Dopamine 0.7 þ 0.3 73 35 þ 13 1.2 þ 0.4 69 44 þ 23
Epinephrine 8.4 þ 2.1 76 430 þ 10 13.5 þ 4.9 70 276 þ 143
Norepinephrine 35.1 þ 7.5 80 2200 þ 894 36.6 þ 6.9 71 1423 þ 258
Data are given as mean þ S.E.M. of three experiments. Competition of [3H]spiperone (200 pM) was performed with 20 increasing concentrations of
ligand ranging from 10312 to 1034 M. Two-site ¢ts were calculated using LIGAND for the Macintosh.
aPercentage of high a⁄nity sites.
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3.2. Comparison of pharmacological pro¢les
It has recently been reported that the D4R receptor can be
functionally activated by three di¡erent catecholamines: dop-
amine (DA), epinephrine (EP), and norepinephrine (NE)
[12,14]. In competition binding experiments with
[3H]spiperone, inhibition constants (Ki values) for the high
a⁄nity binding sites of DA, EP, and NE were found to be
0.7, 8.4, and 35 nM, respectively in CHO-hD4.4-A1 crude
membranes, consistent with previously reported values [12].
In each case, high a⁄nity sites represented about 75% of
the total binding sites. No signi¢cant di¡erences were detected
between the hD4.4-A1 and D4.4-A2 membranes with respect
to Ki values or percentage of high a⁄nity binding sites, which
varied from 70 to 80% in each case (Table 1).
The pharmacological pro¢les of CHO-hD4.4-A1 and CHO-
hD4.4-A2 membranes were further extended to include other
dopaminergic compounds, as well as selected antipsychotic
and antidepressant drugs. Quinpirole, a dopaminergic agonist,
showed approximately two-fold lower a⁄nity at the A2 var-
iant, but no di¡erences in Ki values were detected between the
A1 and A2 variants for apomorphine, lisuride, 7-OH-DPAT,
bromocryptine, butaclamol or L745870, a new D4R speci¢c
antagonist [15] (Table 2). Raclopride and sulpiride showed
very low a⁄nity for both A1 and A2 isoforms.
Eight antipsychotic compounds were tested including halo-
peridol, which showed approximately 3 nM a⁄nity for both
A1 and A2 variants. Clozapine showed a slight preference for
the A1 allele, however there was less than two-fold di¡erence
in a⁄nity compared to the A2 allele (25.5 þ 2.4 vs. 17 þ 0.2
nM for A1 and A2, respectively). Loxapine, risperidone, thi-
oridazine, chlorpromazine, and pimozide all showed high af-
¢nity binding to the D4R, but no di¡erences in Ki values
between the A1 and A2 variants were identi¢ed.
Among the ¢ve antidepressant compounds tested, only clo-
mipramine bound with appreciable a⁄nity to the D4R show-
ing similar Ki values of 97 and 91 nM for A1 and A2 variants,
respectively. Doxepine and mianserine showed weak a⁄nity
for the D4R, with Ki values of 275 þ 17 and 488 þ 93 nM at
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Table 2




(3)Apomorphine 0.58 þ 0.09 0.67 þ 0.01
Lisuride 2.6 þ 0.2 2.2 þ 0.2
Quinpirole 4.2 þ 0.7 8.0 þ 1.6
7-OH-DPAT 39.5 þ 1.9 47.4 þ 3.9
Bromocryptine 130 þ 41 138 þ 52
Dopaminergic antagonists
L745870 0.78 þ 0.03 0.60 þ 0.08
Butaclamol 107 þ 8 76.8 þ 1.4
Raclopride 4450 þ 330 3765 þ 475
Antipsychotics
Haloperidol 3.3 þ 0.3 3.4 þ 1.5
Loxapine 7.2 þ 1.0 7.8 þ 1.0
Risperidone 7.4 þ 1.8 5.5 þ 0.7
Thioridazine 8.7 þ 2.0 7.3 þ 0.2
Chlorpromazine 11.0 þ 0.7 7.8 þ 0.5
Pimozide 12.6 þ 2.0 9.5 þ 0.5
Clozapine 25.5 þ 2.3 17.0 þ 0.2
Sulpiride 862 þ 114 1100 þ 403
Antidepressants
Chlorimipramine 97.1 þ 5.7 90.6 þ 4.3
Doxepine 275 þ 17 260 þ 19
Mianserine 488 þ 93 370 þ 40
Fluvoxamine s 1e35 s 1e35




Clonidine s 1e35 s 1e35
DOI s 1e35 s 1e35
NMDA s 1e34 s 1e34
DZP s 1e34 s 1e34
DMCM s 1e34 s 1e34
Ro 15-4513 s 1e34 s 1e34
D-Cycloserine s 1e34 s 1e34
L-DOPA s 1e34 s 1e34
Data are given as mean þ S.E.M of three experiments. Competition of
[3H]spiperone (200 pM) was performed with 20 increasing concentra-
tions of ligand ranging from 10312 M to 1034 M.
DOI, 4-iodo-2,5-dimethoxyphenylisopropylamine; NMDA, N-meth-
yl-D-aspartate; DZP, diazepam; DMCM, ethyl 4-ethyl-6,7-dime-
thoxy-9H-pyrido[3,4-b]indole-3-carboxylate.
Fig. 2. Saturation binding and Scatchard transformation of
[3H]spiperone binding to A1 and A2 D4R variants expressed in
CHO cells. CHO-hD4.4-A1 and CHO-hD4.4-A2 cell membranes
(30^35 Wg/assay) were incubated with [3H]spiperone at 0.01^3 nM
(n = 3) for 90 min at RT in the dark. Non-speci¢c binding was de-
termined in the presence of 10 WM (+)butaclamol. Scatchard analy-
sis was performed using EBDA for Macintosh, and representative
curves are shown. KD values of 371 þ 30 pM and 357 þ 40 pM
(n = 3) were determined for A1 and A2 D4R variants, respectively.
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the A1 allele, respectively, and no detectable di¡erences de-
tected between the A1 and A2 variants. Fluvoxamine and
£uoxetine showed no interaction with either D4R isoform.
Other compounds with little or no detectable a⁄nity for either
isoform included clonidine, D-cycloserine, L-DOPA, 5-HT,
NMDA, and the serotonergic compounds DOI and 8-OH-
DPAT. The benzodiazepines diazepam (DZP) and DMCM
did not interact with either D4R variant, nor did Ro 15-
4513, a weak inverse agonist which binds the diazepam-insen-
sitive K6 subunit of the GABAA receptor.
3.3. Functional characterization
We have used an [35S]GTPQS binding assay to compare
hD4R activation in membranes prepared from CHO-hD4.4-
A1 and CHO-hD4.4-A2 cells. In this assay the degree of stim-
ulation is proportional to the level of receptor expression, as
shown in Fig. 3A. DA-induced stimulation of [35S]GTPQS
binding reached 95% of basal levels in CHO-hD4.4-A2 mem-
branes, where D4R expression levels were exactly 2.0 pmol/mg
protein. CHO-hD4.4-A1 membranes, with a D4R expression
level of 0.65 pmol/mg protein, had DA-induced stimulation
levels of 58%. Despite the di¡erence in expression levels,
nearly identical EC50 values of 91 þ 4 and 95 þ 6 nM (n = 3)
were determined for CHO-hD4.4-A1 and CHO-hD4.4-A2
membranes, respectively. To con¢rm that the higher A2 ex-
pression level was not concealing a lower agonist potency, a
second cell clone expressing lower levels of the A2 isoform
(CHO-hD4.4-A2-low) was also characterized. CHO-hD4.4-
A2-low membranes had a receptor expression level of 0.34
pmol/mg protein with 32% stimulation over basal, and
showed an EC50 value for DA of 80 þ 5 nM, consistent with
that obtained with the CHO-hD4.4-A1 and CHO-hD4.4-A2
membranes. Thus, no signi¢cant di¡erence between the A1
and A2 D4R variants with respect to potency of DA stimu-
lation was detected.
In order to investigate possible di¡erences in functional
blockade of the D4R, antagonism of DA-induced
[35S]GTPQS binding by haloperidol (10312^1034 M) was eval-
uated. IC50 values of 101 þ 18, 91 þ 11, and 115 þ 45 nM were
determined for CHO-hD4.4-A1, CHO-hD4.4-A2, and CHO-
hD4.4-A2-low membranes, respectively, demonstrating no sig-
ni¢cant di¡erence between the A1 and A2 variants (Fig. 3B),
as predicted from the similar Ki values obtained in competi-
tion binding assays.
4. Discussion
In stably transfected CHO cell lines expressing the hD4.4R,
the pharmacological pro¢les of the A1 and A2 D4R variants
were found to be nearly identical with respect to neurotrans-
mitter binding (DA, EP, and NE) and a⁄nity for the anti-
psychotic drugs tested including haloperidol, risperidone, and
chlorpromazine. Minor di¡erences were observed for cloza-
pine, which showed almost two-fold higher binding a⁄nity
for the A2 variant, while the dopaminergic agonist quinpirole
had slightly higher a⁄nity for the A1 variant. However, func-
tional activation of A1 and A2 D4R variants by dopamine,
and antagonism of this response by haloperidol, were not
signi¢cantly di¡erent in an in vitro [35S]GTPQS binding assay.
Three adrenergic antagonists ^ yohimbine, prazosin, and
propranolol ^ have previously been shown to be inactive at
the D4R [12], despite the ability of EP and NE to act as
potent agonists at this receptor. In this study we show that
clonidine, another K receptor antagonist, also shows no a⁄n-
ity to the D4R. Antidepressant drugs tested here included the
selective serotonin uptake inhibitors £uoxetine (Prozac) and
£uvoxamine, which were inactive at the D4R as expected.
Mianserine, a tetracyclic compound, showed low a⁄nity to
the D4R, while the two tricyclics doxepine and clomipramine
showed signi¢cant receptor a⁄nity. Clomipramine has also
been reported to show moderate a⁄nity to the D2R in vitro
[16].
The lack of signi¢cant di¡erences between A1 and A2 var-
iants suggests that the N-terminal region of the D4R is not
directly involved in receptor activation. This is consistent with
the ¢nding that DFR1, a monoclonal antibody raised against
the extreme N-terminus of the D4R, did not alter DA-induced
receptor activation or antagonism by haloperidol [11]. In im-
munoblotting experiments, we have found that both A1 and
A2 D4R variants are labeled by DFR1, which was expected
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Fig. 3. Evaluation of A1 and A2 D4R functional properties as
measured by [35S]GTPQS binding assays. A: CHO-hD4.4-A1 (¢lled
circles), CHO-hD4.4-A2 (¢lled squares), and CHO-hD4.4-A2-low
(open circles) cell membranes were incubated with increasing con-
centrations of dopamine. Maximal receptor activation at the 100%
level corresponded to 25 000 speci¢c dpm. EC50 values of 91 þ 4,
95 þ 6, and 80 þ 5 nM (n = 3) were determined for A1, A2, and A2-
low membranes, respectively. B: DA-induced [35S]GTPQS binding in
CHO-hD4.4-A1 (¢lled circles), CHO-hD4.4-A2 (¢lled squares), and
CHO-hD4.4-A2-low (open circles) cell membranes is inhibited with
similar potency by the neuroleptic haloperidol (IC50 values 101 þ 18,
91 þ 11, and 115 þ 45 nM, respectively).
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since the DFR1 epitope does not overlap with the exon 1
polymorphic region.
Our results suggest that the di¡erence in response to neuro-
leptic drug treatment observed in delusional disorder patients
may not be a direct consequence of the 12 bp polymorphism
in exon 1, however the functional relevance of the A2 allele in
a complex disorder such as psychosis may only be detected
when expressed in the appropriate genetic background. Fur-
ther experiments should explore the pharmacology of A1 and
A2 isoforms when these sequences are combined with other
D4R polymorphismic variants, for instance D4.7-A1 vs. D4.7-
A2, or D4.2-A1 vs. D4.2-A2 alleles. Investigation of receptor-
mediated cAMP accumulation and sodium sensitivity of li-
gand binding, paradigms in which the D4.7 variant shows
somewhat altered responses [10,17], might also be used to
reveal subtle di¡erences. Importantly, additional studies of
patient populations will be required to understand how this
variation, perhaps in combination with other genetic and en-
vironmental factors, may confer susceptibility to delusional
disorder.
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